Context Therapeutics (NASDAQ:CNTX) Inc, the women's cancer-focused group, has said its compounds are set to be showcased at the upcoming American Association for Cancer Research (AACR) annual meeting between April 8 and 13, 2022.
Five abstracts have been selected for poster or symposium presentations at the event in New Orleans, Louisiana.
"We look forward to the presentations from investigators on lead product candidate onapristone extended release (ONA-XR), a potent, specific progesterone receptor (PR) antagonist being evaluated for PR+ breast, ovarian and endometrial cancer, and our preclinical anti-claudin 6 (CLDN6) bispecific monoclonal antibody (BsMAb) for gynecologic cancer therapy," said Martin Lehr, CEO of Context Therapeutics in a statement.
Dr Joseph Rucker will present a session entitled: 'Atomic-level specificity of Claudin 6 monoclonal antibodies isolated for treating solid tumors' on April 10.
READ: Context Therapeutics adds two new executives to strengthen its research and development team
The same day, Dr Elisabetta Marangoni will present: 'Targeting progesterone receptor (PR) with the antiprogestin onapristone in patient-derived xenograft (PDX) models of estrogen receptor positive (ER+), PR positive (PR+) bone metastasis of breast cancer'.
On April 11, Dr Lauryn Werner will present: 'Progesterone promotes immunomodulation and tumor development in the murine mammary gland', while, the same day, Dr Rucker again has: 'Development of claudin 6 bispecific antibodies for treatment of ovarian cancer'.
Finally, on April 12, Dr Antonio D'Assoro presents: 'PR/STAT3 nuclear transcriptional complexes mediate aurora-A kinase-induced stemness plasticity in ER+ breast cancer'.
For more information and to view the abstracts, people are asked to visit the AACR annual meeting website HERE.
On April 13, Context will host a webinar with its management team and AACR presenters, to discuss the results from these presentations and provide updates on the ONA-XR clinical program. To register for this webinar, please click HERE.
Based in Philadelphia, Context is a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers.
Its clinical program for lead candidate onapristone extended release (ONA-XR) consists of three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian, and endometrial cancer.
ONA-XR is a novel, first-in-class small molecule under development as a potent and specific antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women's cancers.
Contact the writer at giles@proactiveinvestors.com